To study the frequency and severity of peripheral neuropathy in multiple system atrophy (MSA), we performed nerve conduction studies in 42 MSA patients suffering from either cerebellar MSA (MSA-C) or parkinsonian MSA (MSA-P). Abnormal nerve conduction was present in 24% of the patients. Abnormalities were significantly more frequent in MSA-P (43%) compared to MSA-C (14%). Motor nerve conduction velocities were reduced in 4% of the MSA-C and in 7% of the MSA-P patients. Abnormal compound muscle action potentials were more frequent in MSA-P (29% versus 7% in MSA-C) pointing to a more pronounced loss of motor axons in this subgroup. Sensory nerve conduction velocities were abnormal in 4% of the MSA-C and 14% of the MSA-P patients, and mean sensory nerve action potentials were normal in all MSA-C and reduced in 7% of the MSA-P patients. The data provide evidence that the peripheral nervous system is differentially affected in MSA-C and MSA-P.

1.
Quinn N: Multiple system atrophy – The nature of the beast. J Neurol Neurosurg Psychiatry 1989(suppl):78–89.
2.
Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP: Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117:835–845.
3.
Daniel SE: The neuropathology and neurochemistry of multiple system atrophy; in Bannister R, Mathias CJ (eds): Autonomic Failure: A Textbook of Disorders of the Autonomic Nervous System. Oxford, Oxford University Press, 1992, pp 564–585.
4.
Schulz JB, Klockgether T, Petersen D, Jauch M, Müller-Schauenburg W, Spieker S, Voigt K, Dichgans J: Multiple system atrophy: Natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994;57:1047–1056.
5.
Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK: Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998;74:189–192.
6.
Pramstaller PP, Wenning GK, Smith SJ, Beck RO, Quinn NP, Fowler CJ: Nerve conduction studies, sekeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:618–621.
7.
Cruz Martinez A, Arpa J, Alonso M, Palomo F, Villoslada C: Transcranial magnetic stimulation in multiple system and late onset cerebellar atrophies. Acta Neurol Scand 1995;92:218–224.
8.
Abele M, Schulz JB, Bürk K, Topka H, Dichgans J, Klockgether T: Evoked potentials in multiple system atrophy (MSA). Acta Neurol Scand, in press.
9.
Sobue G, Terao S, Kachi T, Ken E, Hashizume Y, Mitsuma T, Takahashi A: Somatic motor efferents in multiple system atrophy with autonomic failure: A clinico-pathological study. J Neurol Sci 1992;112:113–125.
10.
Terao S, Sobue G, Hashizume Y, Mitsuma T, Takahashi A: Disease-specific patterns of neuronal loss in the spinal ventral horn in amyotrophic lateral sclerosis, multiple system atrophy and X-linked recessive bulbospinal neuronopathy, with special reference to the loss of small neurons in the intermediate zone. J Neurol 1994;241:196–203.
11.
Montagna P, Martinelli P, Rizzuto N, Salviati A, Rasi F, Lugaresi E: Amyotrophy in Shy-Drager syndrome. Acta Neurol Belg 1983;83:142–157.
12.
Galassi G, Nemni R, Baraldi A, Gibertoni M, Colombo A: Peripheral neuropathy in multiple system atrophy with autonomic failure. Neurology 1982;32:1116–1121.
13.
McLeod JG, Evans WA: Peripheral neuropathy in spinocerebellar degenerations. Muscle Nerv 1981;4:51–61.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.